Document Type : Research Articles
Department of Medical Oncology, Yuzuncu Yil University Medical School, Van, Turkey.
Department of Medical Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Department of Radiation Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Department of Medical Oncology, University of Healt Sciences, Erzurum Bölge Training and Research Hospital, Erzurum, Turkey.
Background: The aim of this study was to investigate the effect of platelet parameters before concurrent
chemoradiotherapy (CCRT) on survival of patients with limited disease small cell lung cancer (LD-SCLC). Methods:
This study consisted of patients who received CCRT due to LD-SCLC in the oncology clinic between 1997-2017.
Examined platelet parameters included total platelet count (TPC), mean platelet volume, platelet distribution width,
and platelet-lymphocyte ratio. The cut-off value for TPC was determined as 306x109/U (sensitivity: 62%, specificity:
75.5%), where patients below or equal to this level was classified as Group I, and those above as Group II. Results:The
study included 90 patients whose mean age was 59 years (range: 42-83) and male ratio was 80.0% (n=72). Near
three-fourths of patients (74.4%) were at clinical stage III. Among stage I-II patients, mOS was found as 126 months
for Group I whereas it had not been reached in Group II (p=0.158). Stage III patients showed significantly lower mOS
for Group 1 (16 [range: 14.1-17.8] months) compared to that in Group 2 (19.0 [range: 15.6-62.8] months; p=0.002).
In multivariate analysis, Eastern Cooperative Oncology Group performance score (p=0.003), clinical stage (p<0.001),
prophylactic cranial irradiation (p=0.004), and TPC (p=0.031) was determined as the most significant factors affecting
survival. Conclusion: Our study suggests association of high baseline levels of TPC to improved survival in patients
scheduled to undergo CCRT for LD-SCLC. Considering easiness and universal availability of TPC measurement,
potential utilization of this biomarker may be promising to predict survival, albeit requiring validation by further
well-designated prospective studies.